Biological strategies for osteoarthritis: from early diagnosis to treatment

Weber, Alexander E.; Bolia, Ioanna K; Trasolini, Nicholas A.

doi:10.1007/s00264-020-04838-w

Cited by 39 publications

(32 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We truly believe that our Special Issue has fulfilled its primary goal, which was to collect papers covering a wide range of perspectives on the biology of OA, thus shedding some light on the most recent findings in the field of diagnostic tools and innovative treatment options [30]. The second aim was to offer our readers a view on the directions that research is taking, in the hope that they can consider something new in their clinical practice or find new paths for their own investigations [31,32].…”

mentioning

confidence: 99%

Osteoarthritis: an ancient disease, an unsolved conundrum

Matteo

Murrell

Görtz

et al. 2021

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

mentioning

confidence: 99%

Osteoarthritis: an ancient disease, an unsolved conundrum

Matteo

Murrell

Görtz

et al. 2021

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

“…miRNA, another molecule of our study, which is a kind of endogenous non-coding RNA category with a post-transcriptional regulation to encoding genes [ 28 ]. miRNAs’ correlation with OA pathogenesis has been dug out recently [ 29 ]. It was reported that the mRNA expression of mir-125a-5p was down-expressed in plasma of patients with knee OA [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

miR-125a-5p-abundant exosomes derived from mesenchymal stem cells suppress chondrocyte degeneration via targeting E2F2 in traumatic osteoarthritis

Xia

Wang

et al. 2021

Bioengineered

View full text Add to dashboard Cite

miRNAs are broad participants in vertebrate biological processes, and they are also the major players in pathological processes. miR-125a-5p was recently found a modulator in the progression of osteoarthritis (OA). Our study was aimed to explore the role and underlying mechanisms of miR-125a-5p-abundant exosomes derived from mesenchymal stem cells (MSC) on OA progression. We separated bone marrow mesenchymal stem cells (BMSCs) as well as the exosomes from traumatic OA patients. The immunofluorescence and cartilage staining were implemented for the observation and the assessment on endocytosis of chondrocytes and exosomal miR-125a-5p efficacy to cartilage degradation. Dual luciferase reporter assay was performed to verified the relationship between miR-125a-5p and E2F2. Then, the function of exosomal miR-125a-5p were examined on chondrocyte degeneration in vitro and in vivo . Our findings indicated that E2F2 expression was elevated while the miR-125a-5p was down in traumatic OA cartilage tissue, showing a negative correlation of the former and the latter. miR-125a-5p targets E2F2 in traumatic OA cartilage tissue and leads to the down-expression of E2F2. The E2F2 expression in chondrocytes was decreased after internalization of exosomes. We additionally found that BMSCs-derived exosomes were rich in miR-125a-5p content and chondrocytes can have it internalized. miR-125a-5p is endowed with a trait of accelerating chondrocytes migration, which is going along with the up-expressions of Collagen II, aggrecan and SOX9 and the down-expression of MMP-13 in vitro . Besides that, the mice model with post-traumatic OA turned out that exosomal miR-125a-5p might beget an alleviation in chondrocyte extracellular matrix degradation. All these outcomes revealed that BMSCs-derived exosomal miR-125a-5p is a positive regulator for chondrocyte migration and inhibit cartilage degeneration We thus were reasonable to believe that transferring of exosomal miR-125a-5p is a prospective strategy for OA treatment.

show abstract

“… 1 To many of the products, however, their clinical and cost effectiveness, protocol optimization and indication specification are still to be proven or validated by clinical trials. 2 , 3 The clinical applications of specific biologics or relevant therapies have been reviewed or analyzed in recent literature. 4 - 6 What is lacking is an overview of the clinical trials used a diverse array of biologics for the treatment of cartilage defect and OA, whether the trials are just initiated, ongoing, or completed, and with or without published results.…”

Section: Introductionmentioning

confidence: 99%

The Current Status of Clinical Trials on Biologics for Cartilage Repair and Osteoarthritis Treatment: An Analysis of ClinicalTrials.gov Data

Zhang

Schon

2022

CARTILAGE

View full text Add to dashboard Cite

Objective Biologics are increasingly used for cartilage repair and osteoarthritis (OA) treatment. This study aimed to provide an overview of the clinical trials conducted on this subject. Design Two-word combinations of two sets of key words “cartilage”; “joint”; “osteoarthritis” and “biologics”; “stem cells”; “cell implantation” were used to search the database of ClinicalTrials.gov and supplemented with searches of PubMed and EMbase. The registered trials were analyzed for clinical conditions, completion status, phases, and investigated biologics. Recently completed trials with posted/published results were summarized. Results From 2000 to 2022, a total of 365 clinical trials were registered at ClinicalTrials.gov to use biologics for cartilage repair and OA treatment. Since 2006, the number of registered trials accelerated at an annual rate of 16.4%. Of the 265 trials designated with a phase, 72% were early Phase 1, Phase 1, and Phase 2. Chondrocytes and platelet-rich plasma (PRP) were studied in nearly equal number of early- and late-stage trials. Mesenchymal stem/stromal cells (MSCs) were the most commonly investigated biologics (38%) and mostly derived from bone marrow and adipose tissue (70%). In last 5 years, 32 of the 72 completed trials posted/published results, among which seven Phase 3 trials investigated chondrocytes, PRP, bone marrow aspirate concentrate, hyaluronic acid, collagen membrane, and albumin. Conclusions There was a rapid increase in the number of registered clinical trials in recent years, using a variety of biologics for cartilage repair and OA treatment. Majority of the biologics still require late-stage trials to validate their clinical effectiveness.

show abstract

Biological strategies for osteoarthritis: from early diagnosis to treatment

Cited by 39 publications

References 96 publications

Osteoarthritis: an ancient disease, an unsolved conundrum

Osteoarthritis: an ancient disease, an unsolved conundrum

miR-125a-5p-abundant exosomes derived from mesenchymal stem cells suppress chondrocyte degeneration via targeting E2F2 in traumatic osteoarthritis

The Current Status of Clinical Trials on Biologics for Cartilage Repair and Osteoarthritis Treatment: An Analysis of ClinicalTrials.gov Data

Contact Info

Product

Resources

About